Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.

Temmerman F, Gevers T, Ho TA, Vanslembrouck R, Coudyzer W, van Pelt J, Bammens B, Pirson Y, Drenth JP, Nevens F

Alimentary pharmacology & therapeutics25 Jun 2013Cited by 31 (Europe PMC)

PMID23799922DOI10.1111/apt.12384PepBankPUB-23799922

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialSafety outcome
In PCLD, severe side effects occurred in 7% with lanreotide 90 mg versus 0% with placebo.
In plain wordsIn PCLD, severe side effects occurred in 7% with lanreotide 90 mg versus 0% with placebo.
Peptide
Lanreotide
Outcome
IncreaseSevere side effects with 90 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
90 mg every 4 weeks · 6 monthsAs given in this study (human).
Measurements
Severe side effects
7%
lanreotide 90 mg, 6 months
Severe side effects
0%
placebo, 6 months
Source sentences
Summary
Severe side effects occurred with placebo, LAN 90 mg and LAN 120 mg in respectively 0%, 7% and 16%.
2 context sentences(design, population, supporting numbers)
Summary · context
The 6-month results of the LOCKCYST I trial, its extension study and the LOCKCYST II trial were pooled.
Summary · context
Each received treatment every 4 weeks during 6 months: placebo (n = 26); LAN 90 mg (n = 55) or LAN 120 mg (n = 51).
Report a problemFND-2379992201
02HumanNon-randomized trialSafety outcome
In PCLD, severe side effects occurred in 16% with lanreotide 120 mg versus 0% with placebo.
In plain wordsIn PCLD, severe side effects occurred in 16% with lanreotide 120 mg versus 0% with placebo.
Peptide
Lanreotide
Outcome
IncreaseSevere side effects with 120 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
120 mg every 4 weeks · 6 monthsAs given in this study (human).
Measurements
Severe side effects
16%
lanreotide 120 mg, 6 months
Severe side effects
0%
placebo, 6 months
Source sentences
Summary
Severe side effects occurred with placebo, LAN 90 mg and LAN 120 mg in respectively 0%, 7% and 16%.
2 context sentences(design, population, supporting numbers)
Summary · context
The 6-month results of the LOCKCYST I trial, its extension study and the LOCKCYST II trial were pooled.
Summary · context
Each received treatment every 4 weeks during 6 months: placebo (n = 26); LAN 90 mg (n = 55) or LAN 120 mg (n = 51).
Report a problemFND-2379992202
03HumanNon-randomized trialEfficacy outcome
In PCLD, liver volume changed by -82 mL [(-285)-(+92)] with lanreotide 90 mg versus +36 mL [(-45)-(+138)] with placebo (three-group P=0.002).
In plain wordsIn PCLD, liver volume decreased by 82 mL with lanreotide 90 mg versus a 36 mL increase with placebo.
Peptide
Lanreotide
Outcome
DecreaseLiver volume change with 90 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
90 mg every 4 weeks · 6 monthsAs given in this study (human).
Measurements
Change in liver volume
−82 mL
lanreotide 90 mg, 6 months
Range of change in liver volume (bracketed in source)
−285 to 92 mL
lanreotide 90 mg, 6 months
Change in liver volume
36 mL
placebo, 6 months
Range of change in liver volume (bracketed in source)
−45 to 138 mL
placebo, 6 months
P value
0.002 P
Kruskal-Wallis across placebo, 90 mg and 120 mg
Source sentences
Summary
Change in LV's after 6 months in these three groups were respectively: increase of +36 mL [(-45)-(+138)]; decrease of -82 mL [(-285)-(+92)] and decrease of -123 mL [(-312)-(+4)] (Kruskal-Wallis One Way anova on Ranks; P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
The 6-month results of the LOCKCYST I trial, its extension study and the LOCKCYST II trial were pooled.
Summary · context
Each received treatment every 4 weeks during 6 months: placebo (n = 26); LAN 90 mg (n = 55) or LAN 120 mg (n = 51).
Report a problemFND-2379992203
04HumanNon-randomized trialEfficacy outcome
In PCLD, liver volume changed by -123 mL [(-312)-(+4)] with lanreotide 120 mg versus +36 mL [(-45)-(+138)] with placebo (three-group P=0.002).
In plain wordsIn PCLD, liver volume decreased by 123 mL with lanreotide 120 mg versus a 36 mL increase with placebo.
Peptide
Lanreotide
Outcome
DecreaseLiver volume change with 120 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
120 mg every 4 weeks · 6 monthsAs given in this study (human).
Measurements
Change in liver volume
−123 mL
lanreotide 120 mg, 6 months
Range of change in liver volume (bracketed in source)
−312 to 4 mL
lanreotide 120 mg, 6 months
Change in liver volume
36 mL
placebo, 6 months
Range of change in liver volume (bracketed in source)
−45 to 138 mL
placebo, 6 months
P value
0.002 P
Kruskal-Wallis across placebo, 90 mg and 120 mg
Source sentences
Summary
Change in LV's after 6 months in these three groups were respectively: increase of +36 mL [(-45)-(+138)]; decrease of -82 mL [(-285)-(+92)] and decrease of -123 mL [(-312)-(+4)] (Kruskal-Wallis One Way anova on Ranks; P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
The 6-month results of the LOCKCYST I trial, its extension study and the LOCKCYST II trial were pooled.
Summary · context
Each received treatment every 4 weeks during 6 months: placebo (n = 26); LAN 90 mg (n = 55) or LAN 120 mg (n = 51).
Report a problemFND-2379992204
05HumanNon-randomized trialSafety outcome
In PCLD treatment periods, severe side effects occurred in 7% with lanreotide 90 mg versus 16% with 120 mg.
In plain wordsIn PCLD treatment periods, severe side effects occurred in 7% with lanreotide 90 mg versus 16% with 120 mg.
Peptide
Lanreotide
Outcome
DecreaseSevere side effects: 90 mg versus 120 mg
Study
n: not reported in source
Comparator
Lanreotide 120 mg every 4 weeks
Outcome group
Adverse events · Whole body
Studied dose
90 mg every 4 weeks · 6 monthsAs given in this study (human).
Measurements
Severe side effects
7%
lanreotide 90 mg, 6 months
Severe side effects
16%
lanreotide 120 mg, 6 months
Source sentences
Summary
Severe side effects occurred with placebo, LAN 90 mg and LAN 120 mg in respectively 0%, 7% and 16%.
2 context sentences(design, population, supporting numbers)
Summary · context
The 6-month results of the LOCKCYST I trial, its extension study and the LOCKCYST II trial were pooled.
Summary · context
Each received treatment every 4 weeks during 6 months: placebo (n = 26); LAN 90 mg (n = 55) or LAN 120 mg (n = 51).
Report a problemFND-2379992205
06HumanNon-randomized trialEfficacy outcome
In PCLD treatment periods, liver volume changed by -123 mL [(-312)-(+4)] with lanreotide 120 mg versus -82 mL [(-285)-(+92)] with 90 mg (three-group P=0.002).
In plain wordsIn PCLD treatment periods, liver volume decreased by 123 mL with lanreotide 120 mg versus 82 mL with 90 mg.
Peptide
Lanreotide
Outcome
DecreaseLiver volume change: 120 mg versus 90 mg
Study
n: not reported in source
Comparator
Lanreotide 90 mg every 4 weeks
Outcome group
Liver fat and liver function · Liver
Studied dose
120 mg every 4 weeks · 6 monthsAs given in this study (human).
Measurements
Change in liver volume
−123 mL
lanreotide 120 mg, 6 months
Range of change in liver volume (bracketed in source)
−312 to 4 mL
lanreotide 120 mg, 6 months
Change in liver volume
−82 mL
lanreotide 90 mg, 6 months
Range of change in liver volume (bracketed in source)
−285 to 92 mL
lanreotide 90 mg, 6 months
P value
0.002 P
Kruskal-Wallis across placebo, 90 mg and 120 mg
Source sentences
Summary
Change in LV's after 6 months in these three groups were respectively: increase of +36 mL [(-45)-(+138)]; decrease of -82 mL [(-285)-(+92)] and decrease of -123 mL [(-312)-(+4)] (Kruskal-Wallis One Way anova on Ranks; P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
The 6-month results of the LOCKCYST I trial, its extension study and the LOCKCYST II trial were pooled.
Summary · context
Each received treatment every 4 weeks during 6 months: placebo (n = 26); LAN 90 mg (n = 55) or LAN 120 mg (n = 51).
Report a problemFND-2379992206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.